Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Reck

Showing results (251-260 of 437) with videos related to

Pageof 44
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 22, 2010
Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancerAlberto Chiappori, Gerold Bepler, Fabrice Barlesi, et al.
Lung Cancer (Auckland, N.Z.)|January 14, 2026
Reduced Claudin-3 Expression Is Linked to Unfavorable Tumor Features and Poor Prognosis in Non-Small Cell Lung CancerNina Schraps, Martin Reck, Birgit Hantzsch-Kuhn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2021
RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-Small Cell Lung CancerKazuhiko Nakagawa, Ernest Nadal, Edward B Garon, et al.
Clinical Lung Cancer|May 12, 2026
ENTRÉE Lung Platform Trial Sub-study 1: Phase II Randomized Efficacy and Safety Analysis of Feladilimab Plus Docetaxel Versus Docetaxel Monotherapy in Advanced/Recurrent NSCLCMarina Chiara Garassino, Sophie Cousin, Benjamin Besse, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 7, 2014
An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancerGiorgio V Scagliotti, Enriqueta Felip, Benjamin Besse, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2008
Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II studyLucio Crinò, Federico Cappuzzo, Petr Zatloukal, et al.
Lung Cancer (Amsterdam, Netherlands)|August 27, 2019
Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studiesKaname Nosaki, Hideo Saka, Yukio Hosomi, et al.
Cancer Science|September 21, 2020
Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAYMakoto Nishio, Takashi Seto, Martin Reck, et al.
JTO Clinical and Research Reports|April 4, 2022
RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With <i>EGFR</i>-Mutated Metastatic NSCLCMakoto Nishio, Kazuto Nishio, Martin Reck, et al.
European Journal of Cancer (Oxford, England : 1990)|February 25, 2018
Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group surveyAntonin Levy, Corinne Faivre-Finn, Baktiar Hasan, et al.
Pageof 44

Showing results (251-260 of 437) with videos related to

Sort By:
Pageof 44
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 22, 2010
Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancerAlberto Chiappori, Gerold Bepler, Fabrice Barlesi, et al.
Lung Cancer (Auckland, N.Z.)|January 14, 2026
Reduced Claudin-3 Expression Is Linked to Unfavorable Tumor Features and Poor Prognosis in Non-Small Cell Lung CancerNina Schraps, Martin Reck, Birgit Hantzsch-Kuhn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2021
RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-Small Cell Lung CancerKazuhiko Nakagawa, Ernest Nadal, Edward B Garon, et al.
Clinical Lung Cancer|May 12, 2026
ENTRÉE Lung Platform Trial Sub-study 1: Phase II Randomized Efficacy and Safety Analysis of Feladilimab Plus Docetaxel Versus Docetaxel Monotherapy in Advanced/Recurrent NSCLCMarina Chiara Garassino, Sophie Cousin, Benjamin Besse, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 7, 2014
An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancerGiorgio V Scagliotti, Enriqueta Felip, Benjamin Besse, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2008
Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II studyLucio Crinò, Federico Cappuzzo, Petr Zatloukal, et al.
Lung Cancer (Amsterdam, Netherlands)|August 27, 2019
Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studiesKaname Nosaki, Hideo Saka, Yukio Hosomi, et al.
Cancer Science|September 21, 2020
Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAYMakoto Nishio, Takashi Seto, Martin Reck, et al.
JTO Clinical and Research Reports|April 4, 2022
RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With <i>EGFR</i>-Mutated Metastatic NSCLCMakoto Nishio, Kazuto Nishio, Martin Reck, et al.
European Journal of Cancer (Oxford, England : 1990)|February 25, 2018
Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group surveyAntonin Levy, Corinne Faivre-Finn, Baktiar Hasan, et al.
Pageof 44